Imunon, Inc. (IMNN)
0.6231
-0.01
(-0.94%)
USD |
NASDAQ |
Nov 16, 11:51
Imunon Enterprise Value : 6.805M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 6.805M |
| November 12, 2026 | 6.853M |
| November 11, 2026 | 7.371M |
| November 10, 2026 | 7.681M |
| November 09, 2026 | 8.382M |
| November 06, 2026 | 8.145M |
| November 05, 2026 | 8.490M |
| November 04, 2026 | 8.532M |
| November 03, 2026 | 8.488M |
| November 02, 2026 | 8.302M |
| October 30, 2026 | 8.550M |
| October 29, 2026 | 8.072M |
| October 28, 2026 | 8.054M |
| October 27, 2026 | 8.340M |
| October 26, 2026 | 10.54M |
| October 23, 2026 | 10.57M |
| October 22, 2026 | 10.66M |
| October 21, 2026 | 10.29M |
| October 20, 2026 | 9.140M |
| October 19, 2026 | 9.016M |
| October 16, 2026 | 9.233M |
| October 15, 2026 | 9.482M |
| October 14, 2026 | 9.358M |
| October 13, 2026 | 9.544M |
| October 12, 2026 | 9.544M |
| Date | Value |
|---|---|
| October 09, 2026 | 9.606M |
| October 08, 2026 | 9.544M |
| October 07, 2026 | 9.979M |
| October 06, 2026 | 9.854M |
| October 05, 2026 | 10.60M |
| October 02, 2026 | 10.85M |
| October 01, 2026 | 11.10M |
| September 30, 2026 | 10.91M |
| September 29, 2026 | 7.210M |
| September 28, 2026 | 7.420M |
| September 25, 2026 | 7.560M |
| September 24, 2026 | 7.280M |
| September 23, 2026 | 7.840M |
| September 22, 2026 | 8.026M |
| September 21, 2026 | 7.653M |
| September 18, 2026 | 7.326M |
| September 17, 2026 | 7.420M |
| September 16, 2026 | 7.560M |
| September 15, 2026 | 7.513M |
| September 14, 2026 | 7.816M |
| September 11, 2026 | 7.840M |
| September 10, 2026 | 7.746M |
| September 09, 2026 | 8.026M |
| September 08, 2026 | 8.166M |
| September 04, 2026 | 8.353M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Altimmune, Inc. | 91.12M |
| Taysha Gene Therapies, Inc. | 967.94M |
| Agenus, Inc. | 487.93M |
| Amgen, Inc. | 292.70B |
| Anika Therapeutics, Inc. | 160.67M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.750M |
| Total Expenses (Quarterly) | 3.750M |
| EPS Diluted (Quarterly) | -0.6412 |
| Earnings Yield | -532.7% |
| Normalized Earnings Yield | -530.85 |